United Therapeutics | UTHR - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Amarin USD 122.8M 25.08M 2025-09
Ardelyx USD 42.72M 47.32M 2025-09
Baxter International USD 1.97B 240M 2025-12
Bayer EUR 5.9B 1.34B 2025-09
BioCryst Pharmaceuticals USD 335.91M 251.83M 2025-12
Biogen USD 3.01B 854.3M 2025-12
BioMarin Pharmaceutical USD 1.31B 61.57M 2025-12
Emergent BioSolutions USD 111.7M 23.9M 2023-12
Esperion Therapeutics USD 92.45M 6.39M 2025-09
Gilead Sciences USD 7.33B 2.19B 2025-09
GlaxoSmithKline GBP 3.3B 303M 2025-09
Halozyme Therapeutics USD 133.82M 285.84M 2025-12
Insmed USD 510.44M 175.68M 2025-12
Ionis Pharmaceuticals USD 2.68B 437M 2025-12
J&J USD 19.71B 1.48B 2025-12
Lexicon Pharmaceuticals USD 21.36M 41.52M 2025-06
Moderna USD 2.6B 1.46B 2025-12
Omeros USD 1.9M 2.36M 2025-06
Pfizer USD 1.34B 295M 2025-09
PTC Therapeutics USD 984.65M 312.03M 2025-12
Regeneron Pharmaceuticals USD 18.87B 16.36B 2025-12
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sarepta Therapeutics USD 801.28M 188.2M 2025-12
Teva Pharmaceutical Industries USD 3.56B 1.35B 2025-12
United Therapeutics USD 1.56B 217M 2025-12
Vertex Pharmaceuticals USD 6.61B 321.1M 2025-12